Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 5/20 | 0.34 |
| ▸ | HSP90AB1 | P08238 | 5/20 | 0.34 |
| ▸ | BRD4 | O60885 | 2/20 | 0.32 |
| ▸ | PTGER1 | P34995 | 6/20 | 0.31 |
| ▸ | HTR6 | P50406 | 1/20 | 0.30 |
| ▸ | MYC | P01106 | 1/20 | 0.30 |
| ▸ | TYMS | P04818 | 1/20 | 0.30 |
| ▸ | RXRA | P19793 | 1/20 | 0.30 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5003209 | 0.81 | CNR1 (0.43) | HSP90AA1HSP90AB1HTR6MAPTMAPK1 | |
| SCHEMBL3698201 | 0.81 | HSP90AA1 (0.44) | HSP90AA1HSP90AB1 | |
| SCHEMBL4787379 | 0.80 | HTR6 (0.46) | HSP90AA1HSP90AB1HTR6MAPTMAPK1 | |
| SCHEMBL12110218 | 0.76 | PTGER1 (0.41) | HSP90AA1HSP90AB1BRD4PTGER1 | |
| SCHEMBL1148585 | 0.76 | HSP90AA1 (0.58) | HSP90AA1HSP90AB1 | |
| SCHEMBL12047249 | 0.76 | HSP90AA1 (0.45) | HSP90AA1HSP90AB1BRD4TYMSRXRA | |
| SCHEMBL1304453 | 0.75 | HSP90AB1 (0.49) | HSP90AA1HSP90AB1 | |
| SCHEMBL12047229 | 0.74 | HSP90AA1 (0.48) | HSP90AA1HSP90AB1PTGER1RXRA | |
| SCHEMBL1148626 | 0.74 | HSP90AA1 (0.36) | HSP90AA1HSP90AB1PTGER1HTR6RXRA | |
| SCHEMBL2268209 | 0.73 | HSP90AA1 (0.46) | HSP90AA1HSP90AB1LMNAMAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150183771-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | SYNTA PHARMACEUTICALS CORP (US) | 2015-07-02 | — | — | US | disclosed |
| US-8927548-B2 | Triazole compounds that modulate HSP90 activity | SYNTA PHARMACEUTICALS CORP. (US) | 2015-01-06 | — | — | US | disclosed |
| US-8318790-B2 | Triazole compounds that modulate HSP90 activity | SYNTA PHARMACEUTICALS CORP. (US) | 2012-11-27 | — | — | US | disclosed |
| US-20120122869-A1 | TRIZAOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | SYNTA PHARMACEUTICALS CORP. | 2012-05-17 | — | — | US | disclosed |
| EP-2034996-A2 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | Synta Pharmaceuticals Corporation (US) | 2009-03-18 | — | — | EP | disclosed |
| US-20080090887-A1 | Heat Shock Protein 90 (HSP90); treating cancer, inflammatory disorders, angiogenesis inhibition, infections; 3-substituted-4-fused(hetero)aryl-5-phenyl-4H-1,2,4-triazoles | SYNTA PHARMACEUTICALS CORP. | 2008-04-17 | — | — | US | disclosed |
| WO-2007139955-A2 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | SYNTA PHARMACEUTICALS CORP. (US) | 2007-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122869-A1 | TRIZAOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | HSP90AB1, HSP90B1, CDC37 | HSP90AA1 4/4885HSP90AB1 1/4885BRD4 502/4885 |
| US-20080090887-A1 | Heat Shock Protein 90 (HSP90); treating cancer, inflammatory disorders, angiogenesis inhibition, infections; 3-substituted-4-fused(hetero)aryl-5-phenyl-4H-1,2,4-triazoles | HSP90AB1, HSP90AA1, HSP90AB2P | HSP90AA1 2/4885HSP90AB1 1/4885BRD4 106/4885 |
| US-20150183771-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | HSP90AB1, HSP90B1, HSP90AA1 | HSP90AA1 3/4885HSP90AB1 1/4885BRD4 177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.